J Korean Orthop Res Soc.
2012 Dec;15(2):72-75.
Atypical Subtrochanteric Femoral Fracture in a Patient with Non-metatatic Breast Cancer on Zoledronic Acid Therapy: A Case Report
- Affiliations
-
- 1Department of Orthopeadic Surgery, Konyang University, College of Medicine, Daejeon, Korea. todayzic@lycos.co.kr
Abstract
- The bisphosphonate is known for its ability to reduce bone loss in osteoporotic and osseous metastatic conditions. The side effects have been reported after long-term bisphosphonate therapy. We report the case of a woman who sustained atypical subtrochanteric femoral fracture while being on zoledronic acid (Zometa(R), Novartis) therapy for more than 4 years.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Atypical Subtrochanteric Femur Fracture in Patient with Metastatic Breast Cancer Treated with Zoledronic Acid
- An Atypical Subtrochanteric Femoral Fracture in a Patient with Multiple Myeloma Received Zoledronic Acid: A Case Report
- Epidemiology and Clinical Features of Atypical Femoral Fractures
- Subtrochanteric Fracture after Cannulatd Screw Fixation of Femoral Neck Fracture in a Child: A Case Report
- Bilateral Subtrochanteric fracture After Pin Removal in Slipped Capital Femoral Epiphysis: A Case Report
